Form 4: Corcept CBO Exercises Options, Sells Shares for Tax

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, exercised 145,000 stock options and subsequently sold 80,284 shares to cover the exercise price and tax obligations.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc. (CORT), reported transactions on December 24, 2025.
• Robb exercised 145,000 stock options at an exercise price of $3.88 per share.
• Concurrently, he disposed of 80,284 shares of common stock at a price of $83.59 per share.
• This disposition was to satisfy the exercise price and tax liability associated with the net (cashless) exercise of options.
• Following these transactions, Robb directly beneficially owns 78,626 shares of common stock.
• This direct ownership includes 1,764 shares underlying unvested restricted stock awards granted on various dates in 2025, which vest 100% on their one-year anniversary.
• Robb also indirectly beneficially owns 23,142 shares (11,571 shares in each of two separate custodial accounts for his children).
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there's a significant sale of shares, it's primarily for tax and exercise cost coverage following a large option exercise. The executive realized substantial value and still retains a meaningful stake, including unvested awards, indicating continued alignment with the company's future.

Positives

• Chief Business Officer Gary Charles Robb exercised 145,000 stock options, indicating a realization of value from previously granted equity.
• The exercise price of $3.88 is significantly lower than the disposition price of $83.59, highlighting substantial unrealized gains on the options.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned and automated trading, which can mitigate concerns about opportunistic insider trading.
• Robb retains a significant direct beneficial ownership of 78,626 shares, plus indirect ownership of 23,142 shares, demonstrating continued alignment with shareholder interests.

Negatives

• A substantial number of shares (80,284) were sold, reducing the direct beneficial ownership of the Chief Business Officer.
• The sale was primarily to cover tax liabilities and the exercise price, which is a common practice but still represents a reduction in insider holdings.

Future Outlook

NA

Industry Context

This filing details routine insider equity transactions for a pharmaceutical company executive. Such transactions are common in the industry as executives manage their equity compensation, often exercising options and selling shares to cover taxes and exercise costs. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• Gary Charles Robb indirectly beneficially owns 11,571 shares in a custodial account for a child and another 11,571 shares in a separate custodial account for another child, both under the Uniform Transfers to Minors Act for which he is custodian.

Stakeholder Impact

• Shareholders may view the exercise of options and subsequent sale for tax purposes as a normal part of executive compensation management. The retention of a significant number of shares, including unvested awards, suggests continued executive alignment with shareholder interests. No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Business Officer exercised a significant number of options and sold a portion to cover taxes and exercise costs. While the sale reduces direct holdings, it's a common and expected event for executives managing equity compensation. The executive still retains a substantial number of shares, including unvested restricted stock, indicating continued vested interest in the company's performance. Without additional company-specific financial or operational news, this filing alone does not warrant a change from a 'hold' position, as it primarily reflects personal financial planning rather than a change in fundamental company outlook.

Keywords

Corcept Therapeutics, CORT, Gary Charles Robb, Chief Business Officer, SEC Form 4, Insider Trading, Stock Options, Equity Compensation, Rule 10b5-1, Share Disposition, Share Acquisition, Restricted Stock Awards